Literature DB >> 2171443

The role of prostanoids in the production of acute acalculous cholecystitis by platelet-activating factor.

D L Kaminski1, C H Andrus, D German, Y G Deshpande.   

Abstract

Gallbladder tissue from patients with acute acalculous cholecystitis contains increased amounts of prostanoids when compared to normal gallbladder tissue. Platelet-activating factor (PAF) is a potent stimulus of eicosanoid formation. It has been implicated as a mediator of acute inflammatory processes and systemic responses to shock. In this study the role of PAF in acute acalculous cholecystitis was evaluated. Anesthetized cats underwent gallbladder perfusion with a physiologic buffer solution containing [14C]polyethylene glycol as a nonabsorbable tracer to quantitate mucosal water absorption. Platelet-activating factor was infused into the hepatic artery for 2 hours. Control experiments were performed when vehicle alone was infused. Experiments also were performed when indomethacin was administered intravenously and when indomethacin and PAF were administered. Gallbladder mucosal absorption/secretion and perfusate and tissue prostaglandin E (PGE) and 6 keto prostaglandin F1 alpha (6-keto PGF1 alpha) levels were evaluated. Gallbladder inflammation was evaluated by beta-glucuronidase and myeloperoxidase tissue concentrations and by a histologic scoring system. Platelet-activating factor eliminated gallbladder absorption and produced net fluid secretion associated with dose-related increases in perfusate PGE concentrations and gallbladder tissue PGE and 6 keto PGF1 alpha levels when compared to control values. Platelet-activating factor produced significant inflammation in the gallbladder with increases in the histologic score of inflammation and tissue lysosomal enzyme activities. Indomethacin significantly decreased the fluid secretion, prostanoid levels, and inflammation produced by PAF. The results suggest that PAF may induce acute gallbladder inflammation associated with systemic stress through a prostanoid-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171443      PMCID: PMC1358278          DOI: 10.1097/00000658-199010000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration.

Authors:  J L Wallace; B J Whittle
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

3.  Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis.

Authors:  W Hsueh; F Gonzalez-Crussi; J L Arroyave
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

Review 4.  Potential role of platelet-activating factor in renal pathophysiology.

Authors:  G Camussi
Journal:  Kidney Int       Date:  1986-02       Impact factor: 10.612

5.  The effect of lysophosphatidylcholine on gallbladder function in the cat.

Authors:  D Neiderhiser; E Thornell; S Björck; J Svanvik
Journal:  J Lab Clin Med       Date:  1983-05

6.  The role of prostaglandins in feline experimental cholecystitis.

Authors:  D L Kaminski; Y G Deshpande; J Qualy; L A Thomas
Journal:  Surgery       Date:  1985-10       Impact factor: 3.982

7.  Indomethacin intravenously--a new way for effective relief of biliary pain: a double-blind study in man.

Authors:  E Thornell; R Jansson; J Svanvik
Journal:  Surgery       Date:  1981-09       Impact factor: 3.982

8.  Potent ulcerogenic actions of platelet-activating factor on the stomach.

Authors:  A C Rosam; J L Wallace; B J Whittle
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

9.  Acute acalculous cholecystitis. An increasing entity.

Authors:  F Glenn; C G Becker
Journal:  Ann Surg       Date:  1982-02       Impact factor: 12.969

10.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

Authors:  P P Bradley; D A Priebat; R D Christensen; G Rothstein
Journal:  J Invest Dermatol       Date:  1982-03       Impact factor: 8.551

View more
  9 in total

1.  Effect of experimental acalculous cholecystitis on gallbladder smooth muscle contractility.

Authors:  H P Parkman; L J Bogar; L L Bartula; A P Pagano; R M Thomas; S I Myers
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

2.  Neurogenic inflammation in cholecystitis.

Authors:  J B Prystowsky; R V Rege
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 3.  Acute acalculous cholecystitis.

Authors:  Philip S Barie; Soumitra R Eachempati
Journal:  Curr Gastroenterol Rep       Date:  2003-08

4.  Lysophosphatidylcholine-stimulated protein and glycoprotein production by human gallbladder mucosal cells.

Authors:  M K Nag; Y G Deshpande; A Li; D Beck; D L Kaminski
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

5.  Gallbladder mucosal protein secretion during development of experimental cholecystitis.

Authors:  D L Kaminski; Y G Deshpande; A Li; F Dysart; M Nag
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

6.  Subtotal laparoscopic cholecystectomy for gangrenous gallbladder during recovery from COVID-19 pneumonia.

Authors:  Andrea Lovece; Emanuele Asti; Barbara Bruni; Luigi Bonavina
Journal:  Int J Surg Case Rep       Date:  2020-06-13

7.  Platelet-activating factor mediates trinitrobenzene induced dysmotility in the left colon.

Authors:  W E Longo; J Standeven; B Chandel; Y Deshpande; A M Vernava; D Kaminski
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

8.  The effect of lysolecithin on prostanoid and platelet-activating factor formation by human gall-bladder mucosal cells.

Authors:  M K Nag; Y G Deshpande; D Beck; A Li; D L Kaminski
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

9.  Clostridium difficile suppresses colonic vasoactive intestinal peptide associated with altered motility.

Authors:  A Nassif; W E Longo; R Sexe; M Stratton; J Standeven; A M Vernava; D L Kaminski
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.